Tag Archives: PTLA

Portola Pharma (PTLA) Receives a Hold from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Hold rating on Portola Pharma (PTLA – Research Report) yesterday and set a price target of $17.00. The company’s shares closed last Monday at $5.92, close to its 52-week low of $5.60. According to

Oppenheimer Keeps Their Hold Rating on Portola Pharma (PTLA)

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Portola Pharma (PTLA – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $8.54, close to its 52-week low of

Cowen & Co. Sticks to Its Buy Rating for Portola Pharma (PTLA)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Portola Pharma (PTLA – Research Report) yesterday and set a price target of $45.00. The company’s shares closed last Monday at $30.49. According to TipRanks.com, Nadeau is a 4-star

Portola Pharma (PTLA) Gets a Buy Rating from Citigroup

Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $44.00. The company’s shares closed last Monday at $27.03. According to TipRanks.com, Nochomovitz is a 4-star analyst with

William Blair Keeps a Buy Rating on Portola Pharma (PTLA)

William Blair analyst Matt Phipps reiterated a Buy rating on Portola Pharma (PTLA – Research Report) yesterday. The company’s shares opened today at $30.94. Phipps wrote: “We are encouraged by the continued growth of Andexxa, particularly with 74% of sales

Analysts Are Bullish on These Healthcare Stocks: Portola Pharma (PTLA), Sarepta Therapeutics (SRPT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Portola Pharma (PTLA – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments. Portola Pharma (PTLA) Cowen & Co.